Abstract

Investigating the efficacy of Yaobitong capsule in reducing pain and influencing interleukin-6 and interleukin-8 factors was the main goal of this research. The division of 80 patients diagnosed with lumbar disc herniation into a control group and an observation group, consisting of 40 patients each, was conducted during the period from June 2022 to June 2023. Throughout the 2 w treatment period, the control group underwent lumbar traction, massage therapy, and the oral administration of loxoprofen sodium capsules, taken at a frequency of one capsule, three times a day. Meanwhile, the same treatment as the control group was undergone by the observation group, with the addition of Yaobitong capsule, administered at a frequency of three capsules, three times a day. Subsequent to 2 w of treatment, a comparison was made between the two groups based on the clinical efficacy, visual analogue scale scores, Oswestry disability index scores, adverse reactions, and serum interleukin-6 and interleukin-8 levels. Additionally, a follow-up evaluation was conducted after 6 mo to appraise the long-term treatment outcomes. Following a treatment duration of 2 w, the observation group demonstrated a notably higher total effective rate (90.00 %) in comparison to the control group (67.50 %), revealing statistical significance (p<0.05). However, post 2 w of treatment, both groups demonstrated a decline in serum interleukin-6 and interleukin-8 levels compared to pre-treatment levels, with the observation group exhibiting lower levels than the control group. The occurrence rate of adverse reactions did not differ remarkably between the two groups (p>0.05). The outcomes of this study illustrate the notable clinical efficacy of Yaobitong capsule in managing pain linked to lumbar disc herniation. It has the potential to effectively alleviate pain, enhance function, and potentially impact inflammatory cytokines.